Koper L H, Frenk L D S, Meeder J G, van Osch F H M, Bruinen A L, Janssen M J W, van 't Hof A W J, Rahel B M
Department of Cardiology, VieCuri Medical Centre, Venlo, The Netherlands.
Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands.
Neth Heart J. 2022 Jul;30(7-8):360-369. doi: 10.1007/s12471-021-01646-8. Epub 2021 Nov 24.
The HEART score is a validated risk stratification tool for chest pain patients presenting to the emergency department and was recently investigated for implementation in a pre-hospital setting. Fingerstick (capillary blood) point-of-care (POC) troponin testing enables quick measurements outside the hospital and seems easier to implement than the current venous blood sampling techniques. This study investigates the diagnostic accuracy of the modified HEART score, integrating fingerstick POC troponin testing, in ruling out acute coronary syndrome (ACS).
The data of 96 patients with chest pain, included in a study investigating a novel POC troponin device under development at the cardiac emergency department, were analysed retrospectively. Based on the patients' admission data and capillary POC high-sensitivity troponin I (hs-cTnI) results, the modified HEART score was determined. The outcome measure, for evaluating the diagnostic accuracy of the modified HEART score, was the occurrence of ACS.
Of the total study population, 33 patients (34%) were diagnosed with ACS. Seventeen patients (18%) were classified as low risk (0-3 points) and one patient (6%) in this group was diagnosed with ACS. The sensitivity and negative predictive value of the modified HEART score was 97.0 and 97.6%, respectively.
The modified HEART score, integrating capillary POC hs-cTnI results, is a promising tool for ruling out ACS in patients with chest pain presenting to the cardiac emergency department. These results encourage prospective investigation into the integration of fingerstick POC troponin testing in the modified HEART score in a pre-hospital setting.
HEART评分是一种用于评估急诊科胸痛患者风险分层的有效工具,最近有人对其在院前环境中的应用进行了研究。指尖(毛细血管血)即时检验(POC)肌钙蛋白检测能够在院外快速检测,且似乎比目前的静脉血采样技术更易于实施。本研究旨在探讨整合指尖POC肌钙蛋白检测的改良HEART评分在排除急性冠状动脉综合征(ACS)方面的诊断准确性。
回顾性分析了96例胸痛患者的数据,这些患者纳入了一项在心脏急诊科对一种正在研发的新型POC肌钙蛋白检测设备进行研究的试验。根据患者的入院数据和毛细血管POC高敏肌钙蛋白I(hs-cTnI)检测结果,确定改良HEART评分。评估改良HEART评分诊断准确性的结果指标为ACS的发生情况。
在整个研究人群中,33例患者(34%)被诊断为ACS。17例患者(18%)被归类为低风险(0 - 3分),该组中有1例患者(6%)被诊断为ACS。改良HEART评分的敏感性和阴性预测值分别为97.0%和97.6%。
整合毛细血管POC hs-cTnI检测结果的改良HEART评分是一种很有前景的工具,可用于排除就诊于心脏急诊科的胸痛患者的ACS。这些结果鼓励对院前环境中指尖POC肌钙蛋白检测整合到改良HEART评分中进行前瞻性研究。